Objective The aim of the study was to investigate the effects of 3 or less quadrivalent human
papillomavirus (HPV) vaccine doses on anogenital warts in both males and females in the …

Abstract Background In 2009, Norway initiated routine quadrivalent HPV (qHPV) vaccination
for girls at 12–13 years of age to protect against virus types causing cervical cancer …

The objective of this study was to estimate the lifetime age-specific cumulative incidence of
self-reported genital warts diagnosis in Slovenia and to explore the association with …

Objectives To estimate the occurrence of and risk factors associated with genital warts in
Danish men Methods We conducted a cross-sectional, questionnaire-based study among …

Background Most individuals are infected with human papillomavirus (HPV) at least once in
their lifetime. Infections with low-risk types can cause genital warts, whereas high-risk types …

This manuscript provides the available data on the burden of human papillomavirus (HPV)
infections and HPV-related diseases in Israel. The incidence of cervical intraepithelial …

The quadrivalent human papillomavirus (HPV) vaccine currently being delivered to
Australian women aged 12–26 years under the National HPV Vaccination Program …

Background Increasing evidence suggests that 1-dose human papillomavirus (HPV)
vaccination may protect significantly against HPV-related disease. We provide nationwide …

Human papillomavirus (HPV) infection is frequent in young women and persistent infection
may lead to cervical cancer. Therefore, vaccination against HPV is recommended for young …

Methods During 6 month (February 2010-July 2010) 20 private gynaecological centers in all
Czech Republic were counting up the number of genital warts cases. Risk factors, therapy …